What is HC Wainwright’s Estimate for ZVRA FY2028 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at HC Wainwright cut their FY2028 earnings per share estimates for Zevra Therapeutics in a research report issued to clients and investors on Wednesday, November 20th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings per share of $2.51 for the year, down from their previous estimate of $2.71. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same period last year, the company earned ($0.40) earnings per share.

ZVRA has been the subject of a number of other reports. Maxim Group lifted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. JMP Securities started coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Stock Up 5.0 %

Shares of NASDAQ ZVRA opened at $9.59 on Thursday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.64. The firm’s 50-day moving average price is $8.16 and its 200-day moving average price is $6.60. The stock has a market capitalization of $511.65 million, a price-to-earnings ratio of -4.63 and a beta of 1.93.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC increased its position in shares of Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the 1st quarter worth $64,000. The Manufacturers Life Insurance Company increased its position in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the third quarter valued at about $92,000. Finally, XTX Topco Ltd acquired a new stake in Zevra Therapeutics in the third quarter worth about $94,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.